{"product_id":"osur-pestle-analysis","title":"(OSUR) OraSure Technologies, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis OraSure Technologies, Inc. PESTLE Analysis helps you quickly grasp political, economic, social, technological, legal, and environmental forces shaping the company; the page shows a real preview of the report so you can judge style and depth, and purchasing the full version delivers the complete ready-to-use, company-specific analysis for strategy, investment, or research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic health procurement across government buyers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure sells into government buyers, public health agencies, hospitals, clinics, and medical practices, so demand can spike fast during screening drives and outbreak response. In 2025, public-sector orders still hinge on tender rules, approval steps, and budget windows, which can delay or bunch shipments. That makes revenue from this channel less smooth than private sales, even when test demand is strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHIV, HCV, and outbreak testing policy support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. sells rapid HIV, HCV, and Ebola tests, so government screening rules matter a lot: CDC reported 39,201 HIV diagnoses in the U.S. in 2023, and policy shifts can move demand fast. Public health guidance also shapes where tests are bought and used, from clinics to outbreak response. When countries or states expand screening, adoption rises; when they tighten reimbursement or guidance, sales can slow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUS and Europe market exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure sells in the U.S., Europe, and other regions, so its 2025 sales and margins can shift with health policy, import rules, and public spending. Political stability matters too: any delay at ports or in approvals can disrupt distribution. The risk is real in Europe, where cross-border trade in medical goods stays tightly regulated.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFederal and state funding for diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic funding still shapes OraSure Technologies, Inc. demand: U.S. HIV prevention and testing programs get about $1.3 billion a year through CDC funding, and COVID-19 test volumes also jump when federal or state purchase programs reopen. If appropriations weaken or reimbursement rules tighten, adoption can slow across professional, prescription, and self-test channels. \u003c\/p\u003e\n\u003cp\u003eIn plain terms, payer policy can move volumes fast. Even a small cut in grant or Medicaid coverage can hit test ordering, while stronger reimbursement lifts use by clinics and at-home buyers. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFunding cuts can lower test volumes.\u003c\/li\u003e\n\u003cli\u003eReimbursement drives end-user adoption.\u003c\/li\u003e\n\u003cli\u003ePublic programs support infectious disease demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGovernment contracts and compliance pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment buyers in health and biosecurity set strict delivery, quality, and record rules, so OraSure Technologies, Inc. must prove every lot, label, and document matches the contract. Big awards can lift scale fast, but one compliance miss can hurt future eligibility with agencies that recheck vendors often.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrict specs raise execution risk\u003c\/li\u003e\n\u003cli\u003eWins can add fast revenue scale\u003c\/li\u003e\n\u003cli\u003eNoncompliance can block repeat awards\u003c\/li\u003e\n\u003cli\u003eScrutiny is highest in biosecurity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure’s Growth Hinges on HIV Policy, Funding, and Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. depends on public health policy, and 2025 funding, tender rules, and reimbursement still drive test orders. U.S. HIV diagnosis totals of 39,201 in 2023 show why screening policy matters. Stronger CDC-backed programs lift volume; cuts can slow it fast.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePolitical factor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. HIV funding\u003c\/td\u003e\n\u003ctd\u003eAbout $1.3B a year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIV diagnoses\u003c\/td\u003e\n\u003ctd\u003e39,201 in 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eGovernment buyers also add compliance risk: every lot, label, and record must meet contract rules.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eExamines how Political, Economic, Social, Technological, Environmental, and Legal forces shape OraSure Technologies, Inc.’s risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick, easy-to-scan PESTLE summary of OraSure Technologies, Inc. that saves time and supports faster strategy discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable list of primary sources (industry reports, FDA filings, company disclosures) to validate OraSure’s market, pricing, and competitive assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwo-division revenue mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. runs two segments: Diagnostics and Molecular Solutions. That mix spreads demand across infectious disease testing, genomic collection, and lab services, so weak sales in one line can be cushioned by the other. In FY2025, this diversification mattered as test demand and lab workflows moved at different speeds across end markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrice-sensitive rapid test markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. sells self-tests and rapid antigen tests in price-sensitive markets, where per-test pricing often sits in the low single digits. If reimbursement weakens or low-cost competitors gain share, unit prices can fall fast, and margins shrink unless volume rises enough to offset it. In 2025, this mattered more as at-home testing demand stayed uneven and buyers pushed for lower prices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercial and academic demand cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc.'s molecular products sell into ancestry, disease-risk, lifestyle, research, and animal-testing markets, so demand often tracks NIH grant timing and lab budgets. NIH funding was about $48.9 billion in FY2024, and when awards or discretionary lab spend slow, test orders can slip.\u003c\/p\u003e\n\u003cp\u003eHigher rates and cautious consumers also hit direct-to-consumer genomics, where purchase timing is optional. In 2025, the Federal Reserve kept the policy rate at 4.25%-4.50%, which can keep financing tight and make economic slowdowns more likely to delay these buys.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational currency exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. faces foreign exchange risk because Europe and other non-U.S. sales are translated back into US dollars, so a weaker euro can cut reported revenue even when local sales hold up. The euro traded near 1.08 US dollars in early 2026, so small FX swings can move results. Import costs and local pricing also squeeze margin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFX can lower reported sales\u003c\/li\u003e\n\u003cli\u003eEUR moves hit US-dollar revenue\u003c\/li\u003e\n\u003cli\u003eImports and pricing affect margin\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWorking capital tied to inventory and kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. ships collection devices, reagents, and full test systems, so working capital can get stuck in inventory fast. Demand swings can force extra stock builds or write-downs, and because many test kits are time-sensitive medical products, slow turns can hurt cash and margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStock levels can rise with demand spikes.\u003c\/li\u003e\n\u003cli\u003eWrite-down risk grows if kits expire.\u003c\/li\u003e\n\u003cli\u003eFast supply control protects cash.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure Faces Price Pressure, Timing Risks, and FX Swings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. is sensitive to price pressure, grant timing, and consumer spending. FY2025 showed that lower-cost testing and optional genomics purchases can slow revenue when buyers cut spend, while higher rates kept financing tight. FX also matters: euro moves can shift reported sales and margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed policy rate\u003c\/td\u003e\n\u003ctd\u003e4.25%-4.50% in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH funding\u003c\/td\u003e\n\u003ctd\u003e$48.9B in FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEUR\/USD\u003c\/td\u003e\n\u003ctd\u003eNear 1.08 in early 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eOraSure Technologies, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact PESTLE analysis of OraSure Technologies, Inc. you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivacy-driven demand for self-testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. benefits from privacy-driven demand because OraQuick offers in-home and self-test HIV options, which help people avoid stigma and clinic visits. The CDC says about 1.2 million people in the U.S. live with HIV, and roughly 13% do not know it, so private testing can reach people who might skip care. Convenience and confidentiality can lift adoption outside clinics, especially for stigma-sensitive conditions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAwareness of HIV and HCV screening\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAwareness drives OraSure Technologies, Inc. demand because HIV and HCV often need early screening, and WHO still estimates about 39.9 million people live with HIV and 50 million have chronic hepatitis C worldwide. Public campaigns lift test uptake, while lower education levels usually cut screening rates and delay diagnosis. That makes OraSure Technologies, Inc. rapid tests most relevant in high-need, awareness-sensitive markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome-based health management habits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHome-based health management habits keep lifting demand for at-home diagnostics, as more people want quick answers and less clinic time. OraSure Technologies, Inc.'s rapid tests match that shift because users can test at home and get results in minutes, which supports direct-to-consumer and pharmacy sales. In 2025, this consumer self-care trend still mattered, with at-home use favoring products that are simple, fast, and easy to buy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePopulation interest in genetics and ancestry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. benefits when interest in personal genomics rises, because its molecular tests support ancestry, disease-risk, and lifestyle analysis. Consumer demand is driven by identity and family history, while preventive health keeps genetics relevant in routine care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher public interest lifts test orders.\u003c\/li\u003e\n\u003cli\u003eAcademic and commercial demand can follow.\u003c\/li\u003e\n\u003cli\u003eGenomics links to family history and prevention.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTrust in noninvasive sample collection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. depends on trust in noninvasive collection because its core products use oral fluid, saliva, and first-void urine. These methods are easier for many patients than blood draws, so they can lift participation and test completion, especially in home or low-barrier settings.\u003c\/p\u003e\n\u003cp\u003eAcceptance also drives repeat use: if users see the process as private, simple, and accurate, they are more likely to come back. OraSure’s oral HIV self-test gives results in about 20 minutes, which supports faster uptake and wider use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNoninvasive collection lowers patient friction.\u003c\/li\u003e\n\u003cli\u003eHigher comfort can raise completion rates.\u003c\/li\u003e\n\u003cli\u003eTrust supports repeat use and adherence.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure Benefits From Persistent HIV Testing Demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSociological demand for OraSure Technologies, Inc. stays strong because privacy, stigma, and convenience shape testing choices. HIV remains a large need state: WHO estimates 39.9 million people live with HIV, and CDC says about 1.2 million in the U.S. have HIV, with 13% undiagnosed. Self-testing and oral-fluid collection fit users who want fast, low-barrier care.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal HIV\u003c\/td\u003e\n\u003ctd\u003e39.9m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. HIV\u003c\/td\u003e\n\u003ctd\u003e1.2m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUndiagnosed\u003c\/td\u003e\n\u003ctd\u003e13%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral fluid diagnostic platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. is a global leader in oral fluid diagnostics, and that platform stays central to its HIV and rapid test offerings. Oral sample collection can be simpler and less invasive than blood-based methods, which helps screening in clinics, public health, and at-home use. In 2025, this technology remained a key part of OraSure’s test portfolio and growth strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid test and immunoassay development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. keeps pushing InteliSwab, OraQuick, immunoassay tests, and reagents because test sensitivity and specificity drive adoption. In regulated diagnostics, even a 1% shift in accuracy can change clinical trust and reimbursement. Stable manufacturing and constant refinement stay critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMolecular collection brands Oragene and ORAcollect\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOragene and ORAcollect are OraSure Technologies, Inc. genomic sample collection tools that preserve DNA\/RNA for research, commercial, and animal testing use. Their quality matters because bad stabilization can hurt sequencing yield and lab turnaround. OraSure Technologies reported net revenue of $202.2 million in fiscal 2024, showing this tech still sits inside a meaningful commercial base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSample stabilization and transport systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. uses collection, stabilization, transport, and storage kits for genetic material to limit sample degradation before lab processing. That matters in distributed testing networks, where delays can hurt result quality and repeatability. Strong transport tech also supports remote and at-home testing at scale.\u003c\/p\u003e\n\u003cp\u003eReliable sample handling helps protect RNA\/DNA integrity across longer shipping windows.\u003c\/p\u003e\n\u003cp\u003eOngoing demand for decentralized diagnostics keeps this a key technology lever.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReduces degradation risk\u003c\/li\u003e\n\u003cli\u003eSupports remote testing\u003c\/li\u003e\n\u003cli\u003eImproves lab-to-field flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDigital and laboratory service integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGenoFIND gives OraSure Technologies, Inc. a lab-services layer beyond physical kits, so the company can keep more of the testing workflow in-house. That matters because integrated digital and lab systems can lift repeat use, improve data continuity, and support higher-value molecular testing. In 2025, OraSure still reported a kit-led model, so service integration can help deepen customer stickiness and broaden wallet share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMoves past one-time kit sales.\u003c\/li\u003e\n\u003cli\u003eSupports linked patient data.\u003c\/li\u003e\n\u003cli\u003eFits higher-value molecular tests.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure’s Sample-Protection Edge Powers Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. depends on oral-fluid and genomic collection tech, where accuracy, stability, and low sample loss shape adoption. Its kit-led model still matters: fiscal 2024 net revenue was $202.2 million. Decentralized testing and longer shipping windows keep sample-preservation tech a key edge.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTech driver\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOral-fluid testing\u003c\/td\u003e\n\u003ctd\u003eEasy, less invasive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA\/RNA kits\u003c\/td\u003e\n\u003ctd\u003eProtect sample quality\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003ctd\u003e$202.2 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and international in vitro diagnostic oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. operates its tests and collection devices under medical device rules, so U.S. sales depend on FDA clearance or authorization when required. International growth is also tied to country-by-country diagnostic approvals, which can slow launches and raise compliance costs. This makes regulatory timing a direct driver of revenue access and margin pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEU regulatory requirements for diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEU sales for diagnostics must meet the In Vitro Diagnostic Regulation (IVDR), which tightened rules on labeling, clinical performance data, and post-market surveillance. The European Commission extended legacy transition deadlines to Dec. 31, 2027 for Class D, Dec. 31, 2028 for Class C, and Dec. 31, 2029 for Class B and sterile Class A devices. For OraSure Technologies, Inc., that means longer approvals, more evidence work, and higher launch costs in Europe.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrivacy laws for genetic and health data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. handles molecular and genetic data, so privacy controls must meet HIPAA and GDPR rules where they apply. Under HIPAA, civil penalties can reach about $2.1 million per violation category each year, while GDPR fines can hit €20 million or 4% of global turnover. Any breach or misuse can trigger legal claims, regulator action, and brand damage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eQuality system and manufacturing controls\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. faces tight legal risk in diagnostics because quality systems and batch records must prove every lot met specs. If manufacturing slips, the FDA can force recalls, shipment holds, or warning letters, and any gap between claimed and actual performance can drive product-liability claims and lost revenue.\u003c\/p\u003e\n\u003cp\u003eThat risk matters most when test accuracy or stability data do not match label claims.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrict QA and traceability are non-negotiable\u003c\/li\u003e\n\u003cli\u003eErrors can trigger recalls and delays\u003c\/li\u003e\n\u003cli\u003eClaim gaps raise legal exposure fast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGovernment contracting and trade compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. sells to government bodies across regions, so public procurement rules, export controls, and customs checks can slow sales and cash collection. A single compliance error can make the Company ineligible for a bid or stop a shipment at the border. This risk matters most in regulated public-health tenders, where document accuracy decides access.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eProcurement rules can delay awards.\u003c\/li\u003e\n\u003cli\u003eExport controls can block shipments.\u003c\/li\u003e\n\u003cli\u003eCustoms errors can raise costs.\u003c\/li\u003e\n\u003cli\u003eCompliance failures can bar contracts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure Faces Rising FDA, Privacy, and EU Compliance Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. faces legal pressure from FDA quality rules, IVDR, and data-privacy laws; each can delay launches, raise cost, or trigger fines. GDPR fines can reach €20 million or 4% of global turnover, while HIPAA penalties can run to about $2.1 million per violation category each year. Recall, customs, and procurement errors can also block revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRisk\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDPR\u003c\/td\u003e\n\u003ctd\u003e€20m or 4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHIPAA\u003c\/td\u003e\n\u003ctd\u003e$2.1m\/category\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIVDR\u003c\/td\u003e\n\u003ctd\u003e2027-2029\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-use collection device waste\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. sells disposable tests and specimen collection tools, so each use creates plastic and biohazard waste that must be sorted and disposed of under regulated medical waste rules.\u003c\/p\u003e\n\u003cp\u003eThe WHO estimates about 15% of healthcare waste is hazardous, which raises handling, transport, and disposal burdens for customers using single-use kits.\u003c\/p\u003e\n\u003cp\u003eStricter state and local waste rules can also lift OraSure Technologies, Inc. compliance costs and make hospital buyers prefer lower-waste designs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePackaging and shipment footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. ships kits, reagents, and lab services across wide geographies, so packaging volume and freight emissions are material. Road transport alone drives about 8% of global energy-related CO2, which makes lighter packs and tighter route planning important. Efficient logistics can cut both shipping cost and environmental impact, especially when order density is uneven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain avoidance through stabilization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMany OraSure Technologies, Inc. products are built for sample stabilization, transport, and storage, which can cut reliance on refrigerated shipping. The International Energy Agency says cooling and refrigeration use about 20% of global electricity, so less cold-chain demand can lower energy use and emissions. Better stabilization also reduces spoilage risk, which matters when samples face longer transit times or warmer routes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply-chain disruption from weather and climate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies, Inc.'s global sourcing and distribution leave it exposed to storms, port delays, and plant downtime. In 2024, Earth hit its warmest year on record at about 1.55°C above pre-industrial levels, and U.S. weather disasters caused over $90 billion in damage, raising the odds of missed production and slower deliveries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStorms can halt suppliers and transport.\u003c\/li\u003e\n\u003cli\u003eClimate shocks can delay output and shipping.\u003c\/li\u003e\n\u003cli\u003eHigher safety stock can reduce stockouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLaboratory and biohazard disposal standards\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. faces strict disposal rules for diagnostic and molecular-testing products because clinical waste, sharps, and biohazards must be segregated and treated under local and national rules. In the United States, the EPA estimates 15% of healthcare waste is hazardous, so product design, labeling, and packaging must support safe end-of-life handling and reduce spill risk.\u003c\/p\u003e\n\u003cp\u003ePublic health and clinical customers also need compliant transport and disposal paths, which can raise costs and affect procurement choices.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eControlled disposal is part of product use.\u003c\/li\u003e\n\u003cli\u003ePackaging must support safe waste handling.\u003c\/li\u003e\n\u003cli\u003eCompliance can affect customer buying decisions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOraSure’s Waste and Shipping Emissions Are Under Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOraSure Technologies, Inc. faces rising environmental pressure from single-use diagnostic waste, since hazardous healthcare waste makes up about 15% of total healthcare waste and must be handled under strict disposal rules.\u003c\/p\u003e\n\u003cp\u003ePackaging and freight also matter: road transport produces about 8% of global energy-related CO2, so lighter packs and tighter shipping routes can cut emissions and cost.\u003c\/p\u003e\n\u003cp\u003eIts sample-stabilization products can reduce cold-chain needs, and the IEA says cooling uses about 20% of global electricity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHazardous healthcare waste\u003c\/td\u003e\n\u003ctd\u003e15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoad CO2 share\u003c\/td\u003e\n\u003ctd\u003e8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCooling electricity use\u003c\/td\u003e\n\u003ctd\u003e20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234703089929,"sku":"osur-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/osur-pestle-analysis.webp?v=1785727851","url":"https:\/\/dcfanalyst.com\/products\/osur-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}